Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2008
04/03/2008WO2008037931A1 Use of compounds of the avermectin family for the treatment of dermatological disorders
04/03/2008WO2008037923A1 New derivatives of 5-thioxilopyranose
04/03/2008WO2008037922A1 Derivatives of 5-thioxylopyranose and use of same for treatment
04/03/2008WO2008037888A2 Tetracyclic compounds, process for the preparation thereof pharmaceutical compositions comprising the same and use thereof as dopaminergic receptor ligands
04/03/2008WO2008037881A2 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
04/03/2008WO2008037880A1 New class of terpene-derived compounds having an antibiotic activity, compositions containing the same ans uses thereof
04/03/2008WO2008037827A1 Use of particular antibacterial compounds, which are derived from alliaceae, as natural additives in animal feed
04/03/2008WO2008037809A1 Transmucosal administration of fibrate compounds and delivery system therefor
04/03/2008WO2008037807A1 Pharmaceutical formulation comprising metformin and repaglinide
04/03/2008WO2008037784A1 Quinolinone derivatives
04/03/2008WO2008037783A1 Process for preparing 2-oxo-2,5-dihydro-1h-pyrido[3,2-b]indole-3-carbonitriles
04/03/2008WO2008037746A1 Pyridooxazepine progesteron receptor modulators
04/03/2008WO2008037716A2 Pharmaceutical compositions comprising nilotinib or its salt
04/03/2008WO2008037681A1 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.
04/03/2008WO2008037628A1 Sulfonamide derivatives
04/03/2008WO2008037626A1 Quinoline derivatives with 5-ht-binding properties
04/03/2008WO2008037557A2 Rapidly solubilising formulation of non-steroidal anti-inflammatory drugs
04/03/2008WO2008037555A1 Ibuprofen-effervescent preparation having a high dissolution rate and method for the production thereof
04/03/2008WO2008037538A2 Modified alkoxyglycerols
04/03/2008WO2008037502A2 Olanzapine pharmaceutical composition with anhydrous lactose
04/03/2008WO2008037484A2 Formulations comprising cyclic compounds
04/03/2008WO2008037482A1 Biofilm-inhibiting effect and anti-infective activity of n,c-linked arylisoquinolines and the use thereof
04/03/2008WO2008037476A1 Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
04/03/2008WO2008037459A1 Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
04/03/2008WO2008037421A2 Pharmaceutical compositions comprising an s1p modulator
04/03/2008WO2008037415A1 Use of theanine for producing a drug for use in the prophylaxis and treatment of psychiatric disorders of the central nervous system, especially of depressions and pains
04/03/2008WO2008037381A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals
04/03/2008WO2008037266A1 Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
04/03/2008WO2008037258A1 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
04/03/2008WO2008037226A2 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
04/03/2008WO2008037182A1 Use of ginsenoside rg1 for treatment of cerebral ischemia and/or diseases or symptoms induced by cerebral ischemia
04/03/2008WO2008037176A1 Transdermal preparations comprising artemisinin and/or its derivatives
04/03/2008WO2008037171A1 A process for preparing a hyaluronic acid gel in the two crosslinking stages
04/03/2008WO2008037074A1 Antimicrobial agents derived from crea
04/03/2008WO2008037072A1 Cathepsin b inhibitors
04/03/2008WO2008037047A1 Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance
04/03/2008WO2008037045A2 Composition containing a mixture of antidepressants for treating premature ejaculation.
04/03/2008WO2008037044A1 Oxcarbazepine-containing oral formulation and a process to obtain the same
04/03/2008WO2008037037A2 Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc.
04/03/2008WO2008037011A1 Polycyclic agents for the treatment of respiratory syncytial virus infections
04/03/2008WO2008022199A3 Apparatus and process for manufacturing food products with omega-3 polyunsaturated fatty acids
04/03/2008WO2008021545A3 Modulators of muscarinic receptors
04/03/2008WO2008021338A3 Tricyclic oxazolidone derivatives useful as pr modulators
04/03/2008WO2008019363A3 2-alkylbenzoxazole carboxamides as 5ht3 modulators
04/03/2008WO2008018783A3 Porphyrin activation by different spectrum electromagnetical waves-new malignant tumour treatment possibilities
04/03/2008WO2008017883A3 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
04/03/2008WO2008017827A3 Azole and thiazole derivatives and their uses
04/03/2008WO2008017721A3 Method of covering self-assembled metal or inorganic monolayer surfaces of gem-bisphosphonic compounds and uses thereof
04/03/2008WO2008017451A3 Intermittent treatment with bone anti-resorptive compounds
04/03/2008WO2008016883A3 Inhibitors of plasma kallikrein
04/03/2008WO2008015563A3 Salts of rosuvastatin and processes for their preparation
04/03/2008WO2008015220A8 Granule and orally disintegrating tablet comprising oxycodone
04/03/2008WO2008015007A3 Use of escin
04/03/2008WO2008015005A3 Polymorphic forms of ziprasidone sulfates
04/03/2008WO2008014291A3 Compounds and compositions as hedgehog signaling pathway modulators
04/03/2008WO2008013925A3 Fungicidal azocyclic amides
04/03/2008WO2008013807A3 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
04/03/2008WO2008012622A3 Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
04/03/2008WO2008010985A3 Phosphorus derivatives as histone deacetylase inhibitors
04/03/2008WO2008008776A3 Hepatitis c virus inhibitors
04/03/2008WO2008006226A8 Transdermal formulations of synthetic cannabinoids and nano colloidal silica
04/03/2008WO2008004190A3 Polymorphic form of duloxetine hydrochloride
04/03/2008WO2008004013A3 Medicament for the enhancement of cognitive function and neuroprotection
04/03/2008WO2008002924A3 Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
04/03/2008WO2008001204A3 Transdermal compositions of pramipexole having enhanced permeation properties
04/03/2008WO2008000731A3 Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
04/03/2008WO2007146983A3 Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
04/03/2008WO2007146796A3 Antiproliferative compounds, compositions and methods of use
04/03/2008WO2007146375A3 Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
04/03/2008WO2007146284A3 Thienopyrimidines useful as modulators of ion channels
04/03/2008WO2007145834A3 Benzamide derivatives and uses related thereto
04/03/2008WO2007143587A8 Drug administration methods
04/03/2008WO2007140263A9 Macrophage migration inhibitory factor antagonists and methods of using same
04/03/2008WO2007140191A3 Glucose transport inhibitors and methods of use
04/03/2008WO2007139860A3 Heterobicylic metalloprotease inhibitors
04/03/2008WO2007139856A3 Heterobicyclic metalloprotease inhibitors
04/03/2008WO2007139413A3 Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride
04/03/2008WO2007135565A3 Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof
04/03/2008WO2007135131A9 Substituted pyrazinone derivatives for use as a medicine
04/03/2008WO2007131973A3 Compositions and methods for modulating the immune system
04/03/2008WO2007131767A3 Novel actives against prostate carcinoma
04/03/2008WO2007131070A3 Compositions, dosage forms and methods of treating emesis
04/03/2008WO2007130429A3 Histone deacetylase and tubulin deacetylase inhibitors
04/03/2008WO2007128674A3 Muscarinic agonists to treat impulse control disorders
04/03/2008WO2007126898A8 Use of ladostigil for the treatment of schizophrenia
04/03/2008WO2007126799A3 Compositions and methods of use for antibodies of c-met
04/03/2008WO2007119028A3 Composition including at least one aqueous phase and at least one fatty phase including ivermectin
04/03/2008WO2007117704A3 Pure isomers of tritoqualine
04/03/2008WO2007115973A3 Food products for hypophosphoric normo-, hyper- and hypoproteic diets, and their use for nutrition of subjects in need of a low phosphorus level diet
04/03/2008WO2007115198A3 Compliant electrical stimulation leads and methods of fabrication
04/03/2008WO2007112052A3 Formulations and methods for vascular permeability-related diseases or conditions
04/03/2008WO2007109288A3 Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
04/03/2008WO2007107878A3 Solid dosage forms of hypnotic agent
04/03/2008WO2007102446A3 Method and composition for treating chronic obstructive pulmonary disease
04/03/2008WO2007101235A3 Improved antitumoral treatments
04/03/2008WO2007100789A3 Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase
04/03/2008WO2007100562A3 Use of dha and ara in the preparation of a composition for reducing triglyceride levels
04/03/2008WO2007098189A3 New crystal forms and pharmaceutical compositions of (+) -r-zileuton
04/03/2008WO2007087452A3 Abuse resistant and extended release formulations and method of use thereof
04/03/2008WO2007086079B1 Sustained release dosage form of phenothiazine derivatives containing channelizer